Linifanib (ABT-869) is primarily used in the treatment of various types of cancer due to its ability to inhibit multiple receptor tyrosine kinases, which play a crucial role in tumor growth and angiogenesis. It has shown potential in targeting cancers such as hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). By blocking the signaling pathways of vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptors (PDGFR), linifanib helps reduce the blood supply to tumors, thereby limiting their growth and spread. Clinical trials have explored its efficacy as a monotherapy or in combination with other anticancer agents, offering hope for improved outcomes in patients with advanced or refractory cancers. However, its use is often associated with managing side effects, including hypertension and fatigue, which require careful monitoring during treatment.